1,131 publications from this institution
This paper investigates the behaviour of concrete-filled steel tubular (CFST) columns and steel tubeconfined reinforced concrete (STCRC) columns when subjected to non-uniform fire conditions. CFST and STCRC columns exhibit enhanced sectional capacity compared to traditional reinforced concrete and demonstrate superior fire performance relative to steel columns. Because of their many advantages, CFST and STCRC columns are widely employed in the construction industry. However, limited research has been conducted on CFST columns and there is a notable absence of studies on STCRC columns exposed to non-uniform fire. Initially, finite element (FE) models of CFST columns and STCRC columns are developed for validation. To validate the models, a comparison of the results of FE models and tests is performed on the basis of temperature distribution, fire resistance and lateral displacement. A parametric analysis is then carried out to examine the impact of the various fire scenarios including 1-sided, 2-sided, 3-sided and 4-sided exposure on CFST and STCRC columns. Finally, the thermal-structural performance of the CFST and STCRC columns is compared. It is observed that the STCRC columns perform better than the CFST columns in nonuniform fire exposure. The observed comparisons and outcomes can help enhance the overall fire resilience of the buildings.
The increasing demand for structural systems that offer speed, efficiency, and resilience in high-rise and modular construction has led to the growing adoption of concrete-filled steel plate composite (CFSPC) walls, which provide faster construction, reduced section sizes, and enhanced load-bearing capacity compared to reinforced concrete (RC) walls. Although the structural behaviour of CFSPC walls has been widely studied, fire design guidance for these systems remains limited. This study investigates the thermal–structural behaviour of CFSPC walls at elevated temperatures using a sequentially coupled approach implemented in Abaqus. The finite-element framework was first validated against published fire test data and then employed to simulate the fire performance of CFSPC walls through 110 models across a range of wall thicknesses, reinforcement axis distances, load ratios, fire exposures, and concrete and steel strengths. Based on the simulation results, the study develops design equations and design tables to be included in AS/NZS2327 standard to facilitate the fire design of CFSPC walls incorporating normal- and high-strength concrete and steel. The findings demonstrate that CFSPC walls exhibit superior fire performance compared to RC walls. This paper provides a code-compliant design approach to ensure the fire safety of CFSPC walls.
2548 Background: The chemokine CCL2 is highly expressed in various malignancies, and is implicated in tumor angiogenesis, proliferation, and metastasis. CCL2 orchestrates tumor-associated macrophage recruitment and osteoclastic differentiation, fostering tumorigenesis and skeletal metastases. CNTO 888 is a human IgG1κ monoclonal antibody with high CCL2 binding affinity and robust preclinical antitumor activity. Methods: CNTO 888 was administered as a 90-minute infusion on days (d) 1, 29 (for pharmacokinetic [PK] assessment) and q14d thereafter. Pre- and post-therapy pharmacodynamic [PD] evaluation included total and free CCL2 in serum, circulating tumor and endothelial cell enumeration, cytokine profiles, mandated paired tumor biopsies (n=6) for tumor CCL2, CCR2 and macrophage subtypes and exploratory diffusion contrast-enhanced computed tomography (n=6). Results: 44 pts (21M/23F) were treated with CNTO 888: 21 pts in dose-escalation cohorts (0.3, 1, 3, 10, and 15 mg/kg) and 23 pts in 2 dose-expansion cohorts (10 and 15 mg/kg). Reversible grade (G) 3 liver enzymes elevation was seen in 1 pt with progressive liver metastases. No other drug-related G3-4 adverse events (AEs) or dose-limiting toxicity (DLT) was seen. G1-2 AEs included fatigue, nausea, vomiting, pruritus, rash, and headache. PK data showed a dose-proportional increase in mean Cmax and AUC with bi- exponential decline and t1/2 of 4.4-6.9 d. Doses of 10 mg/kg q14d achieved steady-state concentrations required for antitumor activity as defined in preclinical models. Dose-dependent increases in bound CCL2 levels of >1,000-fold were demonstrated. Antitumor activity was observed in 4 pts; CA125 response and RECIST stable disease (SD) for 10 months (m) in ovarian cancer, PSA response and SD for 5m in prostate cancer, 7m SD in ocular melanoma and 15m SD in neuroendocrine tumor. Conclusions: CNTO 888 is well tolerated with no DLT. PKs are dose proportional, with evidence of PD target modulation and antitumor activity. The recommended phase II dose for single-agent CNTO 888 is 15 mg/kg q14d. Phase II studies are ongoing in prostate and planned in ovarian cancer. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Johnson & Johnson, Ortho Biotech Johnson & Johnson Chemotherapy Foundation, Johnson & Johnson Johnson & Johnson
Objective To study apoptosis-inducing activity of allicin in human laryngeal squamous cell carcinoma strain Hep-2.Methods Using techniques of tumor cells culture in vitro Hep-2 cells were exposed to different concentration allicin as 12.5,25.0,50.0,100.0μg /ml,growth characteristics of Hep-2 cells were studied by light microscope,MTT assay and flow cytometry.Results In normal contrast group.Hep-2 cells grew intensively and contacted with each other.However,cells which were treated with lower dose allicin were declined greatly.In higher dose allicin group,necrosis could be found.MTT assay showed that allicin inhibited growth of laryngeal cell with dose and time dependence manner.Flow cytometry showed that allicin could block cell growth at G0/G1 phase,inducing apoptosis of laryngeal cell.Conclusions Human laryngeal squamous cell carcinoma strain Hep-2 can be inhibited and induced into apoptosis by treated with allicin.
Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition with olaparib.
